Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: China NMPA approves Zai Lab’s TIVDAK for recurrent or metastatic Cervical cancer Zai Lab has received approval from China’s National Medical Products Administration for TIVDAK for the […]
Weekly Digest – June 2026 Weekly Digest – June 2026 11 June 2026: CDSCO approves Trastuzumab deruxtecan plus Pertuzumab for first-line HER2-positive metastatic Breast cancer AstraZeneca Pharma India has received CDSCO approval for Enhertu in combination with pertuzumab as a […]
Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: China NMPA grants IND clearance to ADRX-0405 for advanced Solid tumors including Prostate cancer Adcentrx Therapeutics has received Investigational New Drug clearance from China’s National Medical Products […]
Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: Merck and Gilead discontinue phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy plus Keytruda in 1L metastatic NSCLC Merck and Gilead have announced the discontinuation of the phase 3 […]
Weekly Digest – June 2026 Weekly Digest – June 2026 09 June 2026: AmMax Bio licenses antibody-drug conjugate technology for Hematological cancers from Lonza AmMax Bio has entered into a licensing agreement with Lonza to access its clinically validated antibody-drug […]
Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: Johnson & Johnson to acquire Firefly Bio to expand oncology pipeline with degrader ADC platform Johnson & Johnson has entered into a definitive agreement to acquire Firefly […]
